ViGenCell Statistics
Total Valuation
ViGenCell has a market cap or net worth of KRW 70.04 billion. The enterprise value is 32.75 billion.
| Market Cap | 70.04B | 
| Enterprise Value | 32.75B | 
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
ViGenCell has 20.45 million shares outstanding. The number of shares has increased by 1.14% in one year.
| Current Share Class | 20.45M | 
| Shares Outstanding | 20.45M | 
| Shares Change (YoY) | +1.14% | 
| Shares Change (QoQ) | +1.28% | 
| Owned by Insiders (%) | 11.89% | 
| Owned by Institutions (%) | n/a | 
| Float | 13.55M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 251.08 | 
| PB Ratio | 1.23 | 
| P/TBV Ratio | 1.26 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
Enterprise Valuation
| EV / Earnings | -2.61 | 
| EV / Sales | 117.39 | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | -3.61 | 
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.77 | 
| Quick Ratio | 5.73 | 
| Debt / Equity | 0.14 | 
| Debt / EBITDA | n/a | 
| Debt / FCF | -0.85 | 
| Interest Coverage | -37.45 | 
Financial Efficiency
Return on equity (ROE) is -20.23% and return on invested capital (ROIC) is -12.17%.
| Return on Equity (ROE) | -20.23% | 
| Return on Assets (ROA) | -11.91% | 
| Return on Invested Capital (ROIC) | -12.17% | 
| Return on Capital Employed (ROCE) | -23.36% | 
| Revenue Per Employee | 4.36M | 
| Profits Per Employee | -196.23M | 
| Employee Count | 64 | 
| Asset Turnover | 0.00 | 
| Inventory Turnover | n/a | 
Taxes
| Income Tax | n/a | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has increased by +20.00% in the last 52 weeks. The beta is 1.06, so ViGenCell's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 | 
| 52-Week Price Change | +20.00% | 
| 50-Day Moving Average | 3,653.00 | 
| 200-Day Moving Average | 3,146.13 | 
| Relative Strength Index (RSI) | 45.21 | 
| Average Volume (20 Days) | 130,103 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, ViGenCell had revenue of KRW 278.95 million and -12.56 billion in losses. Loss per share was -650.72.
| Revenue | 278.95M | 
| Gross Profit | 4.30M | 
| Operating Income | -13.56B | 
| Pretax Income | -12.56B | 
| Net Income | -12.56B | 
| EBITDA | -10.23B | 
| EBIT | -13.56B | 
| Loss Per Share | -650.72 | 
Balance Sheet
The company has 45.02 billion in cash and 7.72 billion in debt, giving a net cash position of 37.29 billion or 1,823.64 per share.
| Cash & Cash Equivalents | 45.02B | 
| Total Debt | 7.72B | 
| Net Cash | 37.29B | 
| Net Cash Per Share | 1,823.64 | 
| Equity (Book Value) | 56.72B | 
| Book Value Per Share | 2,790.82 | 
| Working Capital | 37.61B | 
Cash Flow
In the last 12 months, operating cash flow was -8.98 billion and capital expenditures -100.04 million, giving a free cash flow of -9.08 billion.
| Operating Cash Flow | -8.98B | 
| Capital Expenditures | -100.04M | 
| Free Cash Flow | -9.08B | 
| FCF Per Share | -444.10 | 
Margins
| Gross Margin | 1.54% | 
| Operating Margin | -4,861.71% | 
| Pretax Margin | -4,502.18% | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
ViGenCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -1.14% | 
| Shareholder Yield | -1.14% | 
| Earnings Yield | -17.93% | 
| FCF Yield | -12.97% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 2.
| Last Split Date | Jun 8, 2022 | 
| Split Type | Forward | 
| Split Ratio | 2 | 
Scores
ViGenCell has an Altman Z-Score of 2.21 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.21 | 
| Piotroski F-Score | 1 |